sodium phenylbutyrate
sodium phenylbutyrate is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand names including Buphenyl, BUPHENYL, OLPRUVA. Available dosage forms: pellet, powder, tablet, kit.
Drug details
- Generic Name
- sodium phenylbutyrate
- Brand Names
- Buphenyl, BUPHENYL, OLPRUVA, sodium phenylbutyrate
- Application Number
- NDA020573
- Sponsor
- Rottendorf Pharma GmbH
- NDC Codes
- 12
- Dosage Forms
- PELLET, POWDER, TABLET, KIT
- Routes
- ORAL
- Active Ingredients
- SODIUM PHENYLBUTYRATE
Indications and Usage
1 INDICATIONS AND USAGE PHEBURANE is indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). Limitations of Use Episodes of acute hyperammonemia may occur in patients while on PHEBURANE. PHEBURANE is not indicated for the treatment of acute hyperammonemia, which can be a life-threatening medical emergency that requires rapid acting interventions to reduce plasma ammonia levels. PHEBURANE is a nitrogen-binding agent indicated as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS). ( 1 ) Limitations of Use PHEBURANE is not indicated for the treatment of acute hyperammonemia. ( 1 )